Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $63.00 price objective on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 300.51% from the company's current price.

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $66.75.

Arcturus Therapeutics Stock Down 3.1 %

ARCT stock traded down $0.51 during mid-day trading on Tuesday, reaching $15.73. 462,703 shares of the stock traded hands, compared to its average volume of 465,731. The firm has a market capitalization of $426.08 million, a PE ratio of -7.30 and a beta of 2.62. The business has a 50-day moving average of $18.75 and a two-hundred day moving average of $22.05. Arcturus Therapeutics has a 52 week low of $14.93 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the previous year, the firm posted ($0.61) EPS. On average, equities research analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Pad Chivukula sold 12,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at $9,037,533.84. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 15.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock worth $52,819,000 after acquiring an additional 712,650 shares in the last quarter. Empire Life Investments Inc. purchased a new position in shares of Arcturus Therapeutics during the third quarter valued at approximately $3,498,000. XTX Topco Ltd purchased a new position in Arcturus Therapeutics during the second quarter valued at $596,000. Squarepoint Ops LLC bought a new position in Arcturus Therapeutics in the 2nd quarter worth about $718,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Arcturus Therapeutics during the third quarter valued at approximately $191,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.